Medicare turned 38 years old in 2003. For most of those years it had operated the way its architects designed it: a public program paying private providers directly, covering every American over 65 regardless of health status, requiring no network enrollment and no prior authorization for most services. The administrative overhead ran around two percent. No shareholders. No marketing budget. No broker commissions.
In November of that year, Congress passed the Medicare Modernization Act. President Bush signed it into law in December. The legislation created Medicare Part D — the prescription drug benefit that 50 million Americans rely on today — and embedded within that popular expansion a restructured private insurance option that would, over the following two decades, become the dominant form of Medicare enrollment in the United States.
That option is Medicare Advantage as it exists today. It did not emerge from evidence that private insurers could administer Medicare more efficiently than the government. It emerged from a specific set of political decisions, made at a specific political moment, under sustained industry pressure, with a payment structure deliberately calibrated to guarantee private insurer participation regardless of whether that participation delivered what its advocates promised.
Understanding how Medicare Advantage was built — the arguments made, the evidence available, the payment structure chosen, and the political infrastructure constructed to protect it — is the foundation for understanding why reforming it has proven so difficult.
Medicare’s First Thirty Years
When Medicare was signed into law in 1965, the insurance industry opposed it. The American Medical Association ran a national campaign against it — Ronald Reagan recorded an LP warning that if Medicare passed, “you and I are going to spend our sunset years telling our children and our children’s children what it once was like in America when men were free.” Medicare passed. It covered 19 million Americans in its first year. It is now politically untouchable — the same party that once called it socialism now campaigns on protecting it.
For the first thirty years, Medicare was a fee-for-service program. Beneficiaries saw any Medicare-participating provider. The government paid claims. The program’s administrative costs were a fraction of what private insurance spent on the same function.
By the late 1980s and early 1990s, Medicare’s long-term financing had become a political concern. The program was growing as the population aged, and projections showed the Hospital Insurance trust fund facing eventual shortfalls. The political debate about Medicare’s sustainability created an opening for an argument that had been circulating in policy circles for years: that managed care — the model Health Maintenance Organizations had developed in the commercial insurance market — could deliver Medicare benefits more efficiently than fee-for-service, reducing costs while maintaining or improving quality.
The HMO argument was not without evidence. HMOs in the commercial market had demonstrated that managed care could reduce hospitalizations and unnecessary procedures. Several Medicare HMO demonstration projects in the 1980s and early 1990s showed lower costs for enrollees who voluntarily participated. The evidence was limited, the selection effects were real — HMOs attracted healthier enrollees, which depressed their costs regardless of how well they managed care — but the argument was available and politically useful.
Congress had authorized a limited Medicare HMO option since the 1970s. By 1995, roughly 10 percent of Medicare beneficiaries were enrolled in managed care plans of various kinds. The case for expanding that option — for making private managed care a more prominent alternative within Medicare — had bipartisan support in a Congress that had just shifted substantially to the right in the 1994 elections.
Medicare+Choice: The First Test
The Balanced Budget Act of 1997 created Medicare+Choice — the first legislative vehicle designed to significantly expand private plan options within Medicare. The program authorized a range of private plan types beyond HMOs, including preferred provider organizations and private fee-for-service plans. The theory was that expanding plan variety and increasing competition would give beneficiaries more choices and drive efficiency through market pressure.
What happened instead was a lesson in the economics of private insurer participation in a public program.
The Balanced Budget Act constrained Medicare+Choice payment rates in an attempt to achieve the savings that were supposed to be the program’s rationale. When rates were held down, insurers discovered they could not make adequate returns on Medicare enrollees — particularly in rural areas and in markets where provider costs were higher. Between 1998 and 2003, more than 2.4 million Medicare beneficiaries were dropped when their plans withdrew from Medicare+Choice entirely. Hundreds of plans exited the program. Counties across the country went from having multiple private plan options to having none.
The lesson the insurance industry drew from Medicare+Choice was direct and would shape what came next: private insurers would not participate in Medicare unless the payment rates were set high enough to guarantee adequate returns. Competition and efficiency were not the organizing principles. Payment rates were.
The lesson Congress drew — or at least the lesson that shaped the next piece of legislation — was that if Medicare privatization was going to work, it would require more generous payment terms for the insurers.
The Medicare Modernization Act: A Payment Structure by Design
By 2002, the political conditions for a major Medicare overhaul had aligned. Republicans controlled both chambers. The Bush administration had made Medicare prescription drug coverage a priority — there was genuine and widespread demand among seniors for a drug benefit that Medicare had never provided. The pharmaceutical and insurance industries recognized an opportunity and invested accordingly.
PhRMA and the insurance industry were among the largest lobbying presences in Washington during the 2002–2003 legislative period. The MMA’s passage involved one of the most intense lobbying campaigns in recent Medicare history — not just for the prescription drug benefit, but for the payment structure that would accompany it.
The Medicare Modernization Act was signed into law in December 2003. Its two major components were Medicare Part D — the prescription drug benefit — and a restructured private plan option renamed Medicare Advantage.
The Part D structure included a provision that would become significant for drug pricing: a non-interference clause prohibiting Medicare from negotiating drug prices with pharmaceutical manufacturers. That provision is examined in the Prescription Drug Pricing hub. What is relevant here is the legislative architecture: a popular benefit — prescription drug coverage — was the vehicle that carried the MA payment structure into law. The two were bundled in a way that made opposition to the MA payment provisions politically costly for members who supported the drug benefit.
The MA payment structure in MMA 2003 was not designed to be actuarially neutral. It was designed to guarantee insurer participation. The legislation set MA benchmark rates — the capitated payments the government would make to insurers — at 107 to 119 percent of projected traditional Medicare costs, depending on the county. The rationale offered was that higher payment rates were necessary to compensate insurers for the risk of taking on Medicare’s sickest beneficiaries and to induce participation in counties that had been abandoned during Medicare+Choice.
MedPAC, the independent agency Congress created to advise on Medicare payment policy, objected at the time. The commission’s analysts noted that setting capitated rates above projected traditional Medicare costs would produce overpayments — that the government would pay more per beneficiary for the same people it could cover less expensively under traditional Medicare. The objection was noted and disregarded. The payment structure was enacted as written.
That payment structure — benchmark rates set above traditional Medicare costs by legislative design — is the origin of the $84 billion annual overpayment the Medicare Payment Advisory Commission reported to Congress in March 2025. The mechanism by which that overpayment is generated is documented in the fifth article in this hub. The point here is simpler: the overpayment was not an accident of program implementation. It was a predictable consequence of a payment structure that was deliberately set above what traditional Medicare would have cost to induce private insurer participation in a public program. MedPAC said so at the time.
The Growth Period: 2003 to 2024
Enrollment in Medicare Advantage grew steadily after 2003 and then accelerated. From approximately five million beneficiaries in 2003, enrollment reached 33 million — more than half of all Medicare enrollees — by 2024. The federal government paid approximately $450 billion to private MA insurers that year.
Several factors drove the growth. The payment structure was generous enough that insurers could offer the extra benefits — dental, vision, hearing coverage — that traditional Medicare did not provide, which made MA plans attractive to newly eligible 65-year-olds comparing their options. The broker commission structure, which paid substantially higher commissions for MA enrollment than for traditional Medicare Medigap policy sales, created a financial incentive for insurance agents to steer beneficiaries toward MA regardless of whether it was the better fit. And the annual enrollment period created a recurring moment of contact between insurers, brokers, and beneficiaries that the traditional Medicare side had no commercial equivalent to.
Through successive administrations — Republican and Democratic — the benchmark payment structure that produced the overpayment was adjusted incrementally but never corrected to eliminate it. Each administration that attempted to recalibrate MA rates downward faced industry resistance and beneficiary backlash. Each administration that proposed expanding MA did so without crediting the overpayment as the funding mechanism for the extra benefits driving enrollment.
The ACA in 2010 included provisions to reduce MA overpayments — a 2012 CBO report found the ACA’s MA payment rate reductions would produce $156 billion in savings over ten years. The insurance industry immediately began working to soften, delay, and reverse those provisions. By 2012, CMS had introduced a quality bonus payment program that effectively restored a significant share of the projected savings. By 2014, an analysis by the Medicare Payment Advisory Commission concluded that the ACA’s MA provisions had saved substantially less than projected.
The Bipartisan Architecture of Durability
Medicare Advantage has survived and grown across administrations because it has built a constituency that spans the partisan divide — not through merit, but through structure.
For Republicans, Medicare Advantage has been defensible as market-based Medicare: private competition delivering public benefits, consistent with the ideological preference for market mechanisms over government administration. When Republicans propose cutting Medicare spending, MA plans are often the vehicle — presented as a premium support or voucher model that introduces market discipline into a program otherwise insulated from competitive pressure.
For Democrats, Medicare Advantage has been difficult to attack because its 33 million enrollees have become a political constituency. Insurers communicate directly and frequently with their enrollees — about the extra benefits their plans provide, about threats to those benefits, about the importance of protecting the program. When reform proposals that would reduce MA overpayments or restrict MA practices emerge, the industry mobilizes that constituency. The political calculation for Democrats who represent large numbers of MA enrollees is not straightforward.
The lobbying infrastructure that sustains this bipartisan durability is substantial. Senate Finance Committee investigation documents more than 220 Capitol Hill lobbyists employed by MA insurers and related interests, with more than $330 million spent on lobbying over a five-year period. The industry’s campaign contribution record reinforces the lobbying investment — money flowing to members of the relevant committees in both parties.
The result is a program that the government’s own analysts have documented as costing substantially more than traditional Medicare, generating tens of billions in annual overpayments, and producing documented harm through prior authorization and network restrictions — and that has nonetheless survived every serious reform attempt for twenty years.
What the Political History Establishes
The political history of Medicare Advantage establishes three things relevant to everything else this hub documents.
First, the program was created not because evidence showed private insurers could deliver Medicare benefits more efficiently, but because the political conditions in 2003 allowed a payment structure that guaranteed private insurer participation regardless of efficiency. The evidence available at the time — from Medicare+Choice’s failure and from MedPAC’s analysis of the proposed MMA payment structure — pointed toward the outcome that followed. That evidence was disregarded.
Second, the overpayment that MedPAC now estimates at $84 billion annually is not a malfunction of the program. It is the program operating as its payment structure requires. The benchmark rates were set above traditional Medicare costs by design. The risk adjustment mechanism that inflates those payments through upcoding — documented in Article 05 — is the exploitation of a payment architecture that was built on above-market rates to begin with.
Third, the political durability of Medicare Advantage is not a consequence of the program working well. It is a consequence of the program building, over twenty years, the enrollment base and lobbying infrastructure needed to protect it from the evidence of how it works. Thirty-three million enrollees receiving regular communications from their insurers, 220 lobbyists on Capitol Hill, and $330 million in lobbying investment are the instruments of that durability — not the program’s record on cost or quality.
The Marketing Machine — Article 03 of this hub — documents how that enrollment base was built. The Financial Structure articles document what the payment architecture produces. The Political Debate articles document what reforming it would require.
The complete Medicare Advantage series
01 — What Medicare Advantage Actually Is — and How It Replaced Traditional Medicare
02 — The Political History: How Private Insurers Got Into Medicare
03 — The Marketing Machine: How Enrollment Works and Who It Targets
04 — Risk Adjustment: The Payment System That Rewards Diagnosis, Not Treatment
05 — The $84 Billion Overpayment: How Upcoding Works at Scale
06 — The Profit Extraction Model: What Insurers Take Before Care Is Delivered
07 — Prior Authorization in Medicare Advantage: What OIG Found
08 — The Denial and Appeals Record: What Happens When Enrollees Push Back
09 — Network Adequacy and the Coverage Gap
10 — The Extra Benefits Myth: Dental, Vision, and What the Fine Print Says
11 — When Medicare Advantage Fails: Disenrollment at the End of Life
12 — The Reform Proposals: From Audit Reform to Elimination
13 — What the Evidence Resolves — and What It Doesn’t
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.